UNSPSC 51313301: Promethazine

This classification denotes a phenothiazine with the molecular formula C17H20N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FF28EJQ494, chemically known as 10h-phenothiazine-10-ethanamine, n,n,alpha-trimethyl-, radical ion(1+) but generally known as promethazine, which bears US NIH Compound Identifier 4927. European Medicines Agency schedules Promethazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10088MIG. The term PROMETHAZINE is an International Non-Proprietary Name.

UNSPSC 51313301 Promethazine is a Commodity code that covers individual pharmaceutical products, but the recent state and local opportunities tagged under it reflect broader pharmaceutical procurement activity spanning naloxone, generic pharmaceuticals, and over-the-counter products rather than promethazine specifically. State and local governments buy finished pharmaceutical inventory under this code through competitive bidding and cooperative purchasing arrangements, typically for community health programs, public health initiatives, and multi-jurisdictional pharmacy benefit programs. Issuing bodies include county health departments, state health and human services commissions, and multi-state cooperative purchasing alliances. The work involves supplying FDA-compliant, manufactured pharmaceuticals with specified National Drug Codes, delivery logistics, compliance with Good Manufacturing Practices and Drug Supply Chain Security Act requirements, and ongoing inventory management through authorized wholesalers.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 (response deadline July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, bidding through electronic procurement with fixed-fee pricing and a two-year term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, exploring direct contracting models outside traditional pharmacy benefit managers and group purchasing organizations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026 (questions due February 18, 2026; proposals due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across Minnesota and Oregon through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with contract awards effective July 1, 2026 and evaluation weighted 75 percent on price competitiveness.